Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Receives Consensus Rating of “Buy” from Analysts

Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) have received a consensus recommendation of “Buy” from the five brokerages that are currently covering the stock, MarketBeat.com reports. Five research analysts have rated the stock with a buy recommendation. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $38.80.

KNSA has been the subject of a number of research reports. Citigroup started coverage on shares of Kiniksa Pharmaceuticals in a report on Thursday, March 13th. They set a “buy” rating and a $40.00 target price for the company. Jefferies Financial Group lifted their target price on Kiniksa Pharmaceuticals from $40.00 to $45.00 and gave the stock a “buy” rating in a report on Tuesday, April 29th. Finally, Wedbush reaffirmed an “outperform” rating and set a $34.00 target price on shares of Kiniksa Pharmaceuticals in a report on Wednesday, April 16th.

Kiniksa Pharmaceuticals Stock Down 3.0 %

Shares of Kiniksa Pharmaceuticals stock opened at $26.95 on Friday. The business has a fifty day simple moving average of $22.07 and a 200-day simple moving average of $21.34. Kiniksa Pharmaceuticals has a fifty-two week low of $17.38 and a fifty-two week high of $28.56. The firm has a market cap of $1.96 billion, a price-to-earnings ratio of -192.51 and a beta of 0.07.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last issued its quarterly earnings results on Tuesday, April 29th. The company reported $0.11 earnings per share for the quarter, beating analysts’ consensus estimates of $0.02 by $0.09. The company had revenue of $137.79 million during the quarter, compared to the consensus estimate of $128.35 million. Kiniksa Pharmaceuticals had a negative net margin of 2.36% and a negative return on equity of 7.31%. Kiniksa Pharmaceuticals’s revenue was up 72.5% on a year-over-year basis. During the same period in the prior year, the company earned ($0.25) EPS. Analysts anticipate that Kiniksa Pharmaceuticals will post -0.55 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, insider Ross Moat sold 18,259 shares of the stock in a transaction that occurred on Monday, April 21st. The shares were sold at an average price of $20.29, for a total value of $370,475.11. Following the completion of the sale, the insider now directly owns 9,415 shares of the company’s stock, valued at $191,030.35. This represents a 65.98 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Mark Ragosa sold 21,254 shares of the business’s stock in a transaction that occurred on Wednesday, April 30th. The shares were sold at an average price of $26.95, for a total value of $572,795.30. Following the completion of the sale, the chief financial officer now directly owns 27,009 shares of the company’s stock, valued at approximately $727,892.55. The trade was a 44.04 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 224,820 shares of company stock valued at $5,386,361. Company insiders own 54.57% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. GAMMA Investing LLC lifted its holdings in Kiniksa Pharmaceuticals by 84.8% in the 1st quarter. GAMMA Investing LLC now owns 1,238 shares of the company’s stock worth $27,000 after purchasing an additional 568 shares during the last quarter. Asset Management One Co. Ltd. bought a new position in shares of Kiniksa Pharmaceuticals in the first quarter valued at approximately $41,000. Wealthquest Corp acquired a new stake in shares of Kiniksa Pharmaceuticals in the first quarter worth $42,000. Lazard Asset Management LLC bought a new stake in shares of Kiniksa Pharmaceuticals during the 4th quarter worth $61,000. Finally, KLP Kapitalforvaltning AS acquired a new position in Kiniksa Pharmaceuticals in the 4th quarter valued at $158,000. Institutional investors and hedge funds own 53.95% of the company’s stock.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.